| Name | Title | Contact Details |
|---|
Phoenix Flavors & Fragrances is a leading developer and manufacturer of customized flavors and fragrances, with over two decades of experience in the industry. The company is dedicated to delivering high-quality, artisanal products that help clients innovate and stay competitive. Phoenix collaborates closely with its customers to create bespoke solutions, ensuring that each product meets the highest standards of quality and performance. Based in New Jersey, Phoenix employs between 501 and 1000 people and has a strong regulatory team and advanced quality assurance laboratories. This enables the company to maintain compliance with industry regulations and adapt to changing consumer preferences. In 2022, Phoenix expanded its capabilities by acquiring Innovative Fragrances, enhancing its offerings in the home fragrance, personal care, candles, and air fresheners markets. The company serves a diverse range of brands across various sectors, including food, beverages, and personal care.
Mokveld Valves BV is a Dutch manufacturer with a history dating back to 1922. Originally a machine repair shop, it evolved into a leader in high-pressure axial flow valve technology. The company specializes in valves designed for rapid and reliable isolation in severe-service applications, such as High-Integrity Pressure Protection Systems (HIPPS) and Emergency Shut Down (ESD) systems. Mokvelds product range includes axial flow valves, axial control valves, angle choke valves, and axial choke valves, all engineered for demanding environments. Their valves are known for features like bubble-tight bi-directional sealing and the ability to operate under full differential pressure. Mokveld serves a global customer base in the energy sector, including oil and gas production, transmission, and processing, as well as the water industry. The company is recognized for its commitment to reliability, safety, and environmental performance.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.